Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2007

01-12-2007 | PRECLINICAL STUDIES

Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile

Authors: F. C. Vasconcelos, C. R. Gattass, V. M. Rumjanek, R. C. Maia

Published in: Investigational New Drugs | Issue 6/2007

Login to get access

Summary

Pomolic acid (PA) is a pentacyclic triterpene which has been previously described as active in inhibiting the growth of K562 cell line—originated from chronic myeloid leukemia (CML) in blast crisis—and its vincristine-resistant derivative K562-Lucena1. In this work, cells from CML patients were treated with PA and the apoptotic index was compared with the multidrug resistance (MDR) profile and clinical status of the patients. Our findings show that PA 12.5 μg/ml at 24 h (p = 0.000), at 48 h (p = 0.012) and at 72 h (p = 0.005) has a potent apoptotic index in CML cells as compared to mononuclear cells from healthy donors. PA was capable to induce apoptosis in cells from CML patients exhibiting functional MDR phenotype but not in P-glycoprotein expression. In addition, PA was effective in chronic as well as in blast phase of CML. Moreover, similar apoptotic index induced by PA was observed in low, intermediate and high-risk Sokal score as well as in samples from the group of patients with clinical resistance to interferon and/or imatinib and non-treated patients. These results suggest that PA may be an effective agent for the treatment of CML.
Literature
1.
Deininger MWN, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356PubMed
2.
Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. (2001) European Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074–3081
3.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037PubMedCrossRef
4.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880PubMedCrossRef
5.
Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M, Pursche S, Bergemann T, Ehninger G, Schleyer E (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18:401–408PubMedCrossRef
6.
Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29PubMedCrossRef
7.
Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 10:2368–2373CrossRef
8.
Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K (2005) Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4:747–752PubMedCrossRef
9.
List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, Appelbaum FR (2002) Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100:1910–1912PubMed
10.
Ehrhardt H, Fulda S, Fuhrer M, Debatin KM, Jeremias I (2004) Betulinic acid-induced apoptosis in leukemia cells. Leukemia 18(8):1406–1412, AugPubMedCrossRef
11.
Fernandes J, Castilho RO, Costa MR, Wagner-Souza K, Kaplan MAC, Gattass CR (2003) Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett 190:165–169PubMedCrossRef
12.
Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC, Capella MA (2001) Multidrug resistance in tumor cells: characterization of the multidrug resistance line K562-Lucena 1. Ann Acad Bras Cienc 73:57–69
13.
Fernandes J, Weinlich R, Castilho RO, Kaplan MAC, Amarante-Mendes GP, Gattass CR (2005) Pomolic acid triggers mitochondria-dependent apoptotic cell death in leukemia cell line. Cancer Lett 219:49–55PubMedCrossRef
14.
Fernandes J, Weinlich R, Castilho RO, Amarante-Mendes GP, Gattass CR (2007) Pomolic acid may overcome multidrug resistance mediated by overexpression of anti-apoptotic Bcl-2 proteins. Cancer Lett 245:315–332PubMedCrossRef
15.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C, Cox C (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British Cooperative Leukaemia Group. Br J Haematol 87:746–754PubMed
16.
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F et al. (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63:789–799PubMed
17.
Silva KL, Vasconcelos FC, Marques-Santos LF, Kwee JK, Maia RC (2003) CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res 27:243–251PubMedCrossRef
18.
Silva KL, Vasconcellos DV, Castro ED, Coelho AM, Linden R, Maia RC (2006) Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 11:277–285PubMedCrossRef
19.
Vasconcelos FC, Cavalcanti GB Jr, Silva KL, de Meis E, Kwee JK, Rumjanek VM, Maia RC (2007) Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res 31:445–454PubMedCrossRef
20.
Cavalcanti GB Jr, da Cunha Vasconcelos F, Pinto de Faria G, Scheiner MA, de Almeida Dobbin J, Klumb CE, Maia RC (2004) Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B Clin Cytom 61:1–8PubMedCrossRef
21.
Michelutti A, Michieli M, Damiani D, Melli C, Geromin A, Russo D, Fanin R, Baccarani M (1994) Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica 79:200–204PubMed
22.
Trindade GS, Capella MA, Capella LS, Affonso-Mitidieri OR, Rumjanek VM (1999) Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein. Photochem Photobiol 69:694–699PubMedCrossRef
23.
Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW (2002) P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9:1266–1272PubMedCrossRef
24.
Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differentiation 11:1028–1037CrossRef
25.
Rosti G, Trabacchi E, Bassi S (2003) Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 88:256–259PubMed
26.
Larsen AK, Escargueil AE, Skladonowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217–229PubMedCrossRef
27.
Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21–23PubMedCrossRef
28.
Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P (1984) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148–3157
29.
Pepper C, Hoy T, Bentley DP (1997) Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 76:935–938PubMed
30.
Noutomi T, Chiba H, Itoh M, Toyota H, Mixuguichi J (2002) Bcl-xL confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol 38:41–48PubMedCrossRef
31.
Shi X, Liu S, Kleeff J, Friess H, Buchler MW (2002) Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis regulating genes. Oncology 62:354–362PubMedCrossRef
32.
Duvvuri M, Krise JP (2005) Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci 10:1499–1509PubMedCrossRef
Metadata
Title
Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile
Authors
F. C. Vasconcelos
C. R. Gattass
V. M. Rumjanek
R. C. Maia
Publication date
01-12-2007
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2007
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-007-9064-5

Other articles of this Issue 6/2007

Investigational New Drugs 6/2007 Go to the issue

PHASE II STUDIES

Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer

PHASE II STUDIES

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

PRECLINICAL STUDIES

Naphthylnitrobutadienes as pharmacologically active molecules: evaluation of the in vivo antitumour activity

PHASE III STUDIES

Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients

PRECLINICAL STUDIES

Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors

PHASE II STUDIES

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits